




## Study Summary

COVID-19 can cause pneumonia. Pneumonia that has not been caught in hospital is called 'Community Acquired Pneumonia' (CAP). Patients who have been diagnosed with Community Acquired Pneumonia (CAP) are treated with antibiotics.

Different antibiotics are used for patients with CAP that are safe and work well. But we don't know which ones work best for COVID-19 patients. This drug trial looks at different treatments to decide the best.

### Randomised, Embedded, Multifactorial Adaptive Platform trial for Community Acquired Pneumonia

#### REMAP-CAP



Patients get the same treatments as they would get in normal clinical care. The only difference is that the study will choose which antibiotic to use by chance instead of the doctor. The trial has an 'adaptive design' which means that the information collected is reviewed often and changes may be made. For example, an antibiotic that clearly works might quickly start being used more generally as part of 'standard treatment' or another antibiotic that looks promising may be added. Information will be collected from patients at a number of hospitals throughout the UK and beyond.

Information on both immediate and longer-term outcomes will be collected in a medical database with personal details protected. These results will be monitored as the research goes along so that they can contribute to national and global advice and approval of future treatments.



Based upon full documentation produced by the study team:  
<https://www.remapcap.org/coronavirus>